TR200200978T2 - Yeni mirtazapin formülasyonu - Google Patents

Yeni mirtazapin formülasyonu

Info

Publication number
TR200200978T2
TR200200978T2 TR2002/00978T TR200200978T TR200200978T2 TR 200200978 T2 TR200200978 T2 TR 200200978T2 TR 2002/00978 T TR2002/00978 T TR 2002/00978T TR 200200978 T TR200200978 T TR 200200978T TR 200200978 T2 TR200200978 T2 TR 200200978T2
Authority
TR
Turkey
Prior art keywords
new
dosage unit
effects
mirtazapine
mirtazapine formulation
Prior art date
Application number
TR2002/00978T
Other languages
English (en)
Inventor
De Nijs Henrik
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200200978(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of TR200200978T2 publication Critical patent/TR200200978T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Aktif terkip maddesi olarak antidepresan mirtazapini içeren yeni bir oral dozaj ünitesi açiklanmistir; buradaki dozaj ünitesi, oral yoldan parçalanan tiptedir. Dozaj ünitesi, oral yoldan uygulamanin ardindan hizli bir sekilde parçalanirken, geleneksel tabletlerle biyoesdegerdedir, fakat yan etkiler, yarar, anksiyolitik etkiler, uykuyu iyilestirici etkiler ve etkinin baslangici açisindan avantajlidir.
TR2002/00978T 1999-10-13 2000-10-09 Yeni mirtazapin formülasyonu TR200200978T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99203338 1999-10-13

Publications (1)

Publication Number Publication Date
TR200200978T2 true TR200200978T2 (tr) 2002-09-23

Family

ID=8240737

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00978T TR200200978T2 (tr) 1999-10-13 2000-10-09 Yeni mirtazapin formülasyonu

Country Status (28)

Country Link
EP (1) EP1223914B1 (tr)
JP (1) JP5561885B2 (tr)
KR (1) KR100708560B1 (tr)
CN (1) CN1173701C (tr)
AR (1) AR026010A1 (tr)
AT (1) ATE274899T1 (tr)
AU (1) AU780379B2 (tr)
BR (1) BR0014593A (tr)
CA (1) CA2386547C (tr)
CO (1) CO5251412A1 (tr)
CZ (1) CZ20021315A3 (tr)
DE (2) DE1223914T1 (tr)
ES (1) ES2194618T3 (tr)
HK (1) HK1046641B (tr)
HU (1) HUP0203148A3 (tr)
IL (2) IL148777A0 (tr)
MX (1) MXPA02003519A (tr)
NO (1) NO20021730L (tr)
NZ (1) NZ518165A (tr)
PE (1) PE20010699A1 (tr)
PL (1) PL200858B1 (tr)
PT (1) PT1223914E (tr)
RU (1) RU2261098C2 (tr)
SK (1) SK6452002A3 (tr)
TR (1) TR200200978T2 (tr)
TW (1) TWI256309B (tr)
WO (1) WO2001026621A2 (tr)
ZA (1) ZA200202293B (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1689371A2 (en) * 2003-11-25 2006-08-16 Aurobindo Pharma Limited Pharmaceutical compositions of mirtazapine
DE102004034043A1 (de) * 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
AU2007221135A1 (en) * 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CN101129341B (zh) * 2006-08-22 2011-06-01 上海医药工业研究院 口内崩解组合物及其制备方法
EP2377522B1 (en) 2010-04-15 2013-01-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
CN102993208B (zh) 2011-11-22 2017-01-18 北京哈三联科技股份有限公司 去甲肾上腺素和选择性五羟色胺受体阻断剂及其应用
JP6199321B2 (ja) * 2012-03-02 2017-09-20 ローズ ファーマシューティカルズ エル．ピー． 不正使用抵抗性の即時放出製剤
CN104095824B (zh) * 2013-04-09 2016-08-31 上海信谊万象药业股份有限公司 一种米氮平缓释片及其制备方法
PL3261645T3 (pl) 2015-02-27 2021-12-06 Dechra Limited Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów
JP6601844B2 (ja) * 2016-12-05 2019-11-06 共和薬品工業株式会社 光安定性に優れたミルタザピン含有医薬製剤
CN111714463B (zh) * 2020-08-14 2022-06-17 华农（肇庆）生物产业技术研究院有限公司 米氮平口服剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
EP0494972B1 (en) * 1989-10-02 1996-11-27 Cima Labs, Inc. Effervescent dosage form and method of administering same
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
JPH0436252A (ja) * 1990-05-30 1992-02-06 Nippon Alkyl Alum Kk 光学活性アルキニルアルコールの製造方法
JP3168695B2 (ja) * 1991-06-14 2001-05-21 三菱化学株式会社 ショ糖脂肪酸エステルの置換度の低下方法
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JPH05163137A (ja) * 1991-12-12 1993-06-29 Shin Etsu Chem Co Ltd 有核顆粒
JPH0737473A (ja) * 1993-07-27 1995-02-07 Murata Mfg Co Ltd 圧力スイッチ
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
JPH10139659A (ja) * 1996-09-10 1998-05-26 Freunt Ind Co Ltd 球形粒子群、その製造方法及びそれを用いた球形粒子製剤
JP3870470B2 (ja) * 1997-02-07 2007-01-17 大正製薬株式会社 マルチプルユニットタイプ徐放性錠剤

Also Published As

Publication number Publication date
EP1223914A2 (en) 2002-07-24
HK1046641A1 (en) 2003-01-24
HUP0203148A2 (hu) 2003-01-28
CZ20021315A3 (cs) 2002-07-17
CA2386547A1 (en) 2001-04-19
WO2001026621A3 (en) 2001-10-11
CO5251412A1 (es) 2003-02-28
EP1223914B1 (en) 2004-09-01
HK1046641B (zh) 2005-04-08
ES2194618T3 (es) 2005-04-01
DE60013466T2 (de) 2005-01-20
RU2002112238A (ru) 2004-01-10
ATE274899T1 (de) 2004-09-15
JP5561885B2 (ja) 2014-07-30
AR026010A1 (es) 2002-12-26
PL354584A1 (en) 2004-01-26
CA2386547C (en) 2010-06-08
SK6452002A3 (en) 2002-09-10
RU2261098C2 (ru) 2005-09-27
BR0014593A (pt) 2002-06-11
AU1023201A (en) 2001-04-23
NZ518165A (en) 2004-03-26
CN1173701C (zh) 2004-11-03
KR20020038946A (ko) 2002-05-24
TWI256309B (en) 2006-06-11
MXPA02003519A (es) 2002-08-20
DE1223914T1 (de) 2003-09-18
PL200858B1 (pl) 2009-02-27
PT1223914E (pt) 2004-11-30
ES2194618T1 (es) 2003-12-01
JP2003511403A (ja) 2003-03-25
HUP0203148A3 (en) 2004-06-28
KR100708560B1 (ko) 2007-04-19
ZA200202293B (en) 2003-06-20
IL148777A (en) 2013-10-31
CN1378452A (zh) 2002-11-06
AU780379B2 (en) 2005-03-17
NO20021730L (no) 2002-05-30
NO20021730D0 (no) 2002-04-12
DE60013466D1 (de) 2004-10-07
PE20010699A1 (es) 2001-07-06
WO2001026621A2 (en) 2001-04-19
IL148777A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
ES2552639T3 (es) Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
ECSP055569A (es) Forma de dosificación de pramipexol en una dosis única diaria
TR200002207T1 (tr) Slekoksib bileşikleri.
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
MX339071B (es) Almidon pregelatinizado en una formulacion de liberacion controlada.
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
NZ507566A (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
TR200003788A2 (tr) Yavaş salımlı oral dozaj bileşim.
NO971206D0 (no) Forlenget-frigjöringsformulering
SE9900961D0 (sv) Novel compounds
YU53101A (sh) Tableta sa produženim oslobađanjem gliklazida posle oralne primene
TR200200978T2 (tr) Yeni mirtazapin formülasyonu
NZ504460A (en) Sustained release formulations containing venlafaxine
SE9802208D0 (sv) Novel compounds
BR0013935A (pt) IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
DK1007006T3 (da) Formulering af cefadroxilmonohydrattablet
BR0112847A (pt) Uso de uma forma de dosagem sólida
AP2003002763A0 (en) Controlled release formulations for oral administration
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
NO20013414L (no) Ny anvendelse av melagatran
ES2305567T3 (es) Formulaciones de tramadol de liberacion sostenida con una eficacia de 24 horas.
SE9802209D0 (sv) Novel compounds
SE0001916D0 (sv) Novel formulation
PE20011080A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno